Modulation of PI3K-LXR alpha-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Pisonero-Vaquero S
  • García-Mediavilla MV
  • Jorquera F
  • Majano PL
  • González-Gallego J
  • Sánchez-Campos S

Grupos

Abstract

There is experimental evidence that some antioxidant flavonoids show therapeutic potential in the treatment of hepatitis C through inhibition of hepatitis C virus (HCV) replication. We examined the effect of treatment with the flavonols quercetin and kaempferol, the flavanone taxifolin and the flavone apigenin on HCV replication efficiency in an in vitro model. While all flavonoids studied were able to reduce viral replication at very low concentrations (ranging from 0.1 to 5 mu M), quercetin appeared to be the most effective inhibitor of HCV replication, showing a marked anti-HCV activity in replicon-containing cells when combined with interferon (IFN)alpha. The contribution of oxidative/nitrosative stress and lipogenesis modulation to inhibition of HCV replication by quercetin was also examined. As expected, quercetin decreased HCV-induced reactive oxygen and nitrogen species (ROS/RNS) generation and lipoperoxidation in replicating cells. Quercetin also inhibited liver X receptor (LXR)alpha-induced lipid accumulation in LXR alpha-overexpressing and replicon-containing Huh7 cells. The mechanism underlying the LXR alpha-dependent lipogenesis modulatory effect of quercetin in HCV-replicating cells seems to involve phosphatidylinositol 3-kinase (PI3K)/AKT pathway inactivation. Thus, inhibition of the PI3K pathway by LY294002 attenuated LXR alpha upregulation and HCV replication mediated by lipid accumulation, showing an additive effect when combined with quercetin. Inactivation of the PI3K pathway by quercetin may contribute to the repression of LXR alpha-dependent lipogenesis and to the inhibition of viral replication induced by the flavonol. Combined, our data suggest that oxidative/nitrosative stress blockage and subsequent modulation of PI3K-LXR alpha-mediated lipogenesis might contribute to the inhibitory effect of quercetin on HCV replication.

Datos de la publicación

ISSN/ISSNe:
0023-6837, 1530-0307

LABORATORY INVESTIGATION  NATURE PUBLISHING GROUP

Tipo:
Article
Páginas:
262-274
PubMed:
24492281
Factor de Impacto:
1,987 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 43

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • HCV replication; lipogenesis; LXR alpha; oxidative stress; PI3K/AKT pathway; quercetin

Proyectos y Estudios Clínicos

DESARROLLO DE UN MODELO HEPATOCELULAR HUMANO DIFERENCIADO PARA ESTUDIOS DE METABOLISMO Y POTENCIAL INDUCTOR DE NUEVOS FARMACOS

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

SAF2003-09353 . 2003

DEVELOPMENT OF A HIGH THROUGHPUT GENOMICS-BASED TEST FOR ASSESSING GENOTOXIC AND CARCINOGENIC PROPERTIES OF CHEMICAL COMPOUNDS IN VITRO

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

CARCINOGENOMICS . COMISION EUROPEA . 2006

LINTOP

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

LSHB-CT-2006-037499 - LINTOP . FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2005

MECANISMOS TRNACRIPCIONALES IMPLICADOS EN LA ETIOLOGIA DEL HIGADO GRASO NO ALCOHOLICO. ESTUDIOS EN UN MODELO CELULAR HUMANO DE ESTEATOSIS Y APLICACION AL TRANSPLANTE DE HEPATOCITOS EN TERAPIA CELULAR.

Investigador Principal: RAMIRO JOVER ATIENZA

PI07/0550 . INSTITUTO DE SALUD CARLOS III . 2007

MECANISMOS TRANSCRIPCIONALES IMPLICADOS EN EL HIGADO GRASO NO ALCOHOLICO DE ORIGEN METABOLICO E IATROGENICO: INFLUENCIA DE LA RESISTENCIA A LA INSULINA

Investigador Principal: RAMIRO JOVER ATIENZA

PI10/00194 . INSTITUTO DE SALUD CARLOS III . 2010

ESTEATOSIS HEPÁTICA POR MEDICAMENTOS: NUEVOS MECANISMOS Y BIOMARCADORES APLICABLES AL DESARROLLO FARMACÉUTICO Y A UNA TERAPIA MÁS RACIONAL EN PACIENTES CON SÍNDROME METABÓLICO.

Investigador Principal: RAMIRO JOVER ATIENZA

PI13/01470 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014

Cita

Compartir